Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects on the Brain of Lupron Induced Hypogonadotropic Hypogonadism With and Without Testosterone Replacement

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00001412
Recruitment Status : Completed
First Posted : November 4, 1999
Last Update Posted : March 4, 2008
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)

Tracking Information
First Submitted Date November 3, 1999
First Posted Date November 4, 1999
Last Update Posted Date March 4, 2008
Study Start Date December 1993
Primary Completion Date Not Provided
Current Primary Outcome Measures Not Provided
Original Primary Outcome Measures Not Provided
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Effects on the Brain of Lupron Induced Hypogonadotropic Hypogonadism With and Without Testosterone Replacement
Official Title The Central Nervous System Effects of Pharmacologically Induced Hypogonadotropic Hypogonadism With and Without Testosterone Replacement
Brief Summary

There is evidence that suggests male sex hormones (androgens) play a significant role in brain (central nervous system) functioning. In studies conducted with animals, researchers have documented that male sex hormones (androgens) are associated with neurotransmitter (serotonin) function, sexual behavior, aggression, and other non-reproductive behavior. Similar findings have been seen in studies involving humans.

Androgens are thought to be involved in some neurologic conditions. Tourette's syndrome which is seen more often in males than females has caused researchers to look more closely at the effects of androgens on the brain.

This study is designed to examine the effects of testosterone on brain (CNS) activity by first stopping testosterone release and then replacing it.

Researchers will evaluate mood, behavior, cognitive (mental) function, physiologic response to serotonergic agonists and regional cerebral blood flow (r-CBF).

This study will attempt to answer the following questions;

1. Is a person's mental functioning a result of being male or female (gender) or a result of the hormonal condition

3. Does the decrease of blood flow (r-CBF) to specific areas of the brain (prefrontal cortex) in women whose ovaries are not releasing hormones (hypogonadal state) also occur in men

4. Will the mental rotation task better identify hormone (gonadal steroid) differences in r-CBF

5. Do hormones directly influence the responsiveness of the hypothalamic-pituitary-adrenal (HPA) axis

6. Does the hormonal state of a patient directly affect levels of chemicals and steroids in the cerebrospinal fluid (CSF).

Detailed Description Several types of evidence suggest that androgens exert clinically significant effects on central nervous system (CNS) function. In animal studies, androgens modulate brain serotonin function, and regulate sexual behavior, aggression, and other non-reproductive behaviors. These actions reflect both organizational and activational effects of androgens. Several studies in humans also support the central modulatory capacity of androgens. Correlative studies have described relationships between plasma androgen levels and sexual interest/behavior and cognitive task performance. Androgens are believed to underlie gender related differences in the prevalence of certain neuropsychiatric disorders, resulting in trials of anti-androgens in at least one of these disorders (Tourette's syndrome). Finally, androgens are believed to possess psychotropic effects in humans, evidenced by purported antidepressant effects and reports of psychotic reactions following administration of androgens. In a recent study, we demonstrated that androgenic/anabolic steroids precipitated mood and behavioral state disturbances when administered in a double-blind, placebo-controlled fashion in normal volunteers. There are remarkably few studies that attempt to identify the CNS effects of androgens or the central systems that may mediate these effects. In this study we propose to examine directly the effects of testosterone on CNS activity by first suppressing and then, in a double-blind, placebo-controlled fashion, replacing physiological levels of testosterone. We will evaluate mood, behavior, cognitive function, physiologic response to serotonergic agonists and cerebral blood flow (separate protocols) during both pharmacologically controlled hormonal conditions: hypogonadism and hypogonadism with testosterone replacement. On the basis of prior findings from our group and from others, we will be asking the following questions: 1) Does cognitive function differ as a function of gender or of hormonal condition; 2) Is the decreased r-CBF that we observed in the prefrontal cortex during the hypogonadal state in women also demonstrable in men; 3) Do measures of hypothalamic-pituitary-adrenal axis responsivity differ as a function of gender or of hormonal condition; and 4) Do CSF neurochemistry and neurosteroid levels differ as a consequence of changing hormonal state. This protocol will not only provide much needed information about the behavioral and physiological effects of androgens but will serve as a companion study for NIMH protocol #92-M-172, "The Central Nervous System Effects of Pharmacologically Induced Hypogonadotropic Hypogonadism with and without Estrogen and Progressive Replacement."
Study Type Observational
Study Design Not Provided
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Not Provided
Study Population Not Provided
Condition Hypogonadism
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Enrollment
 (submitted: June¬†23,¬†2005)
70
Original Enrollment Same as current
Study Completion Date November 2001
Primary Completion Date Not Provided
Eligibility Criteria

Age 18-45.

Males.

No current mood symptoms.

No past psychiatric history.

Not taking ongoing medications.

No medical illnesses.

Sex/Gender
Sexes Eligible for Study: Male
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT00001412
Other Study ID Numbers 940037
94-M-0037
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Not Provided
Study Sponsor National Institute of Mental Health (NIMH)
Collaborators Not Provided
Investigators Not Provided
PRS Account National Institutes of Health Clinical Center (CC)
Verification Date November 2001